Inovio Pharmaceuticals, Inc.

LSE:0A43 Voorraadrapport

Marktkapitalisatie: US$141.5m

Inovio Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Inovio Pharmaceuticals is forecast to grow earnings and revenue by 36.4% and 75.8% per annum respectively while EPS is expected to grow by 43.9% per annum.

Belangrijke informatie

36.4%

Groei van de winst

43.9%

Groei van de winst per aandeel

Biotechs winstgroei37.3%
Inkomstengroei75.8%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt04 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

LSE:0A43 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202617-117-74-274
12/31/20250-131-126-1056
12/31/20240-127-135-946
6/30/20241-122-113-112N/A
3/31/20241-125-117-116N/A
12/31/20231-135-125-124N/A
9/30/20231-165-135-134N/A
6/30/202310-168-173-173N/A
3/31/202310-241-192-191N/A
12/31/202210-280-217-216N/A
9/30/202211-332-219-218N/A
6/30/20222-355-198-197N/A
3/31/20222-328-226-225N/A
12/31/20212-304-217-216N/A
9/30/20217-221-231-229N/A
6/30/20216-142-258-257N/A
3/31/20216-188-207-205N/A
12/31/20207-166-179-178N/A
9/30/20202-180-141-140N/A
6/30/20203-222-94-94N/A
3/31/20203-123-91-91N/A
12/31/20194-119-99-98N/A
9/30/20196-115-103-101N/A
6/30/20197-117-100-98N/A
3/31/201932-94-95-93N/A
12/31/201830-97-76-74N/A
9/30/201837-86-72-70N/A
6/30/201837-95-68-63N/A
3/31/201833-97N/A-61N/A
12/31/201742-88N/A-63N/A
9/30/201742-93N/A-64N/A
6/30/201752-80N/A-65N/A
3/31/201738-89N/A-62N/A
12/31/201635-74N/A-63N/A
9/30/201633-65N/A-54N/A
6/30/201644-39N/A-20N/A
3/31/201644-27N/A-16N/A
12/31/201541-29N/A-12N/A
9/30/201537-19N/A-14N/A
6/30/201515-31N/A-37N/A
3/31/201513-36N/A-36N/A
12/31/201410-36N/A-30N/A
9/30/201410-44N/A-21N/A
6/30/201417-68N/A-19N/A
3/31/201414-68N/A-16N/A
12/31/201313-66N/A-15N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 0A43 is forecast to remain unprofitable over the next 3 years.

Winst versus markt: 0A43 is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: 0A43 is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: 0A43's revenue (75.8% per year) is forecast to grow faster than the UK market (3.6% per year).

Hoge groei-inkomsten: 0A43's revenue (75.8% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if 0A43's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven